Rahway, N.J. — January 27, 2026 — Leads & Copy — Merck’s Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the second quarter of 2026, the company announced today.
The payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026.
Merck, known as MSD outside of the United States and Canada, is focused on using science to save and improve lives around the world. For more than 130 years, the company has developed medicines and vaccines and aspires to be a research-intensive biopharmaceutical company, delivering health solutions that advance the prevention and treatment of diseases in people and animals.
The company also said that it fosters a diverse and inclusive global workforce and operates responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Source: Merck
